Why is Syncom Formulations (India) Ltd falling/rising?

Short-Term Price Movement and Market Context

Syncom Formulations’ share price gained ₹0.68 on 28 January, outperforming its sector by 5.24%. This rebound is significant given the stock’s recent downward trajectory, marking a recovery after two days of consecutive falls. The stock’s current price sits above its 5-day moving average, indicating some immediate buying interest, although it remains below the 20-day, 50-day, 100-day, and 200-day moving averages. This suggests that while short-term momentum is positive, the broader trend remains subdued.

Liquidity conditions remain adequate, with the stock’s trading volume on 27 January recorded at 7.62 lakh shares. However, this represents a 38% decline compared to the five-day average delivery volume, signalling a drop in investor participation. Lower volumes can sometimes temper the sustainability of price moves, implying that the recent rise may be driven by selective buying rather than broad market enthusiasm.

Comparative Performance Against Benchmarks

Examining Syncom Formulations’ returns relative to the Sensex reveals a mixed picture. Over the past week, the stock has surged by 6.80%, significantly outpacing the Sensex’s modest 0.53% gain. This short-term outperformance aligns with the recent price uptick and suggests some renewed investor interest.

However, the stock’s performance over longer horizons has been less encouraging. Over one month, Syncom Formulations declined by 12.96%, compared to a 3.17% drop in the Sensex. Year-to-date, the stock is down 11.98%, while the benchmark has fallen by 3.37%. The one-year return is particularly stark, with the stock losing 25.19% against the Sensex’s 8.49% gain. These figures highlight persistent challenges for the company’s shares amid broader market strength.

On a more positive note, the stock has delivered robust returns over the medium and long term. Over three years, it has appreciated by 62.48%, outperforming the Sensex’s 38.79% gain. The five-year performance is even more impressive, with a 297.47% rise compared to the benchmark’s 75.67%. This long-term outperformance underscores the company’s underlying growth potential despite recent volatility.

Technical and Market Implications

The recent price rise after a short-term decline suggests that investors may be viewing the current levels as an attractive entry point. The stock’s position above the 5-day moving average indicates some immediate buying momentum, but the fact that it remains below longer-term moving averages points to resistance ahead. This technical setup often signals a cautious market stance, where traders await further confirmation before committing to sustained buying.

Falling delivery volumes, however, caution against over-optimism. Reduced investor participation can limit the strength of upward moves and increase the risk of volatility. Market participants should therefore monitor volume trends closely to assess whether the recent gains can be maintained or if they represent a temporary bounce.

In summary, Syncom Formulations (India) Ltd’s 5.72% rise on 28 January reflects a short-term recovery amid a backdrop of longer-term underperformance relative to the broader market. While the stock’s recent outperformance against the Sensex and sector is encouraging, investors should weigh this against subdued volumes and technical resistance levels. The company’s strong medium- and long-term returns provide a foundation for optimism, but near-term caution remains warranted.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →